Brief: PeptiDream enters into collaboration with Janssen Pharmaceuticals

PeptiDream

07/04/2017 11:09

April 7 (Reuters) - PeptiDream Inc  4587.T  
     
     
    * Says it entered into a multitarget discovery and 
optimization collaboration with Janssen Pharmaceuticals, inc, 
one of the Janssen Pharmaceutical Companies of Johnson & Johnson 
 JNJ.N , on April 7 
    * Says it will use its proprietary Peptide Discovery 
Platform System (PDPS) technology to identify 
macrocyclic/constrained peptides against multiple metabolic and 
cardiovascular targets of interest selected by Janssen, and to 
optimize hit peptides into therapeutic peptides or small 
molecule products 
    * Says Janssen also holds an exercisable option to 
peptide-drug conjugate (PDC) use and applications 
    * Says Janssen will have the right to develop and 
commercialize all compounds resulting from the collaboration 
    * Says it will receive undisclosed upfront payment and 
research funding and is eligible to receive preclinical, 
clinical, and commercialization milestone payments potentially 
totaling up to $1.15 billion 
    * In addition, it is eligible to receive royalties on sales 
of any products that arise from the collaboration 
     
    Source text in Japanese:https://goo.gl/xI06yf 
    Further company coverage: 4587.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; 82555111; Reuters 
Messaging: Pingping.Li@thomsonreuters.com@reuters.net))